VYSCOXA (Celecoxib) Patent Expiration, LOE Window & CMS Spending

VYSCOXA (Celecoxib) by Carwin Associates: FDA Orange Book core substance LOE 2045-09-17, 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCarwin Associates
FDA Application & PathwayN211759 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2045-09-17
Last Listed Patent or Exclusivity Date2045-09-17
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel